Loading
STI-6129 is an experimental antibody-drug conjugate from Zhejiang ACEA Pharmaceutical in phase 2 trials for multiple myeloma, aimed at CD38.
STI-6129 is an antibody-drug conjugate developed by Zhejiang ACEA Pharmaceutical. Its target is CD38 (the sponsor names CD38). The sponsor states: Anti-CD38 human antibody covalently bound to a duostatin tubulin inhibitor payload. ClinicalTrials.gov describes the intervention as: Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT05565807, plans to enrol 84 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Anti-CD38 human antibody covalently bound to a duostatin tubulin inhibitor payload. Connects to CD38.
1.STI-6129's antibody arm binds CD38 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"STI-6129" OR ABSTRACT:"STI-6129") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STI-6129, not a curated reading list.
Shares CD38, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.